Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 European Hematology Association Congress

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330 against advanced chronic myeloid leukemia (CML) will be presented in the CML Biology oral abstract session at the 18th Congress of the European Hematology Association (EHA) to be held June 13th – 15th, 2013 in Stockholm, Sweden.

Help employers find you! Check out all the jobs and post your resume.

Back to news